Fras Qiwei Wu Yu Du Sirel Gurbuz Tamer Coskun Axel Haupt Zvonko Milicevic Mark L
Nausea, vomiting, stomach cramps, bloating, constipation, and diarrhea are the most common, along with fatigue, headaches, and dizziness
Eli Lilly is conducting multiple phase 3 trials
Concerns have arisen regarding compounded versions of GLP-1 drugs, with the FDA receiving over 700 adverse event reports due to dosing errors or unapproved formulations
Interaction risk may increase with other serotonergic medicines and supplements
Last, we call upon clinicians, researchers, regulators, and industry stakeholders to address existing gaps in accessibility and explore opportunities for enhancing the use of GLP-1R agonists in both individualized care and broader public health contexts